Why Restaurant Operator Darden Shares Are Slipping Today

Darden Restaurants Inc (NYSE: DRI) reported second-quarter FY24 sales growth of 9.7% year-on-year to $2.727 billion, missing the 

Darden Restaurants Inc (NYSE:DRI) reported second-quarter FY24 sales growth of 9.7% year-on-year to $2.727 billion, missing the analyst consensus estimate of $2.741 billion.

The sales growth was driven by a blended same-restaurant sales increase of 2.8% and sales from the addition of 78 company-owned Ruth’s Chris Steak House restaurants and 45 other net new restaurants.

Darden clocked an operating margin of 10.2%, and the operating income rose 19.4% Y/Y to $278.5 million. Adjusted EPS of $1.84 beat the consensus estimate of $1.74.

Darden generated an operating cash flow of $609.9 million for six months. It held $219.9 million in cash and equivalents as of November 26, 2023. Inventories at the end of Q2 were $310.6 million.

Darden’s Board of Directors declared a quarterly cash dividend of $1.31 per share on the common stock, payable on February 1, 2024, to shareholders of record on January 10, 2023.

As of Q2-end, the company had approximately $328 million remaining under the current $1 billion repurchase authorization.

Outlook: Darden sees FY24 adjusted EPS from continuing operations of $8.75-$8.90 (estimate $8.81), excluding approximately $0.37, after-tax, of Ruth’s Chris transaction and integration related costs.

The company previously expected adjusted EPS from continuing operations of $8.55-$8.85, including Ruth’s Chris operating results, but excluding approximately $55 million, pre-tax, of expected transaction and integration related costs.

DRI sees FY24 revenue of $11.5 billion versus an estimate of $11.57 billion. While announcing its Q4 FY23 results, DRI expected FY24 total sales of $11.5 billion-$11.6 billion.

Price Action: DRI shares are trading lower by 1.7% at $160.30 in premarket on the last check Friday.

Photo Via Company

Total
0
Shares
Related Posts
Read More

SEC Green Lights Public Listing Of Texas Cannabis Co. That Will Use AI In Clinical Trials

Cannabis Bioscience, a Houston-based clinical research company, has announced plans to conduct cannabis clinical trials using artificial intelligence (AI) programs. The company aims to optimize the research processes and promote the use of cannabinoid therapies as a first option for patients. Proceeds from a stock offering by selling shareholders will be used to fund these trials.

CBIH